Skip to main content

Table 2 Quantification of kif21b expression in situ

From: Abundant kif21b is associated with accelerated progression in neurodegenerative diseases

Patient id Age at death Gender Presenting symptom Time to EDSS 6.0 (years) Neuropathology assessment Kif21b1 Kif21b genotype
Braak stage Amyloid Neu-rons Glia cells
NDC2 49 F NA NA 0 ND + - GA
NDC4 53 F 0 0 +/- - GA
NDC6 56 F 0 0 +/- - GG
NDC8 62 F 1 0 +/- - GA
NDC10 70 F 0 B + + GA
NDC13 50 M 1 0 - - AA
NDC29 77 M 1 B +/- / + - GG
NDC30 78 M 1 A +/- +/- AA
NDC36 82 M 1 A +/- - GG
MS4 50 F Myelitis 7 ND ND - - GG
MS6 56 F ND 4* ND ND + + GG
MS8 63 F Optic neuritis 17 0 0 + - GA
MS10 70 F Cerebrum 30 1 0 - - GG
MS23 56 M Myelitis 2 ND ND - - AA
MS25 57 M Myelitis 6 ND ND +/- - GG
MS40 74 M Myelitis 8 3 0 - - AA
AD2 57 F NA NA 6 C + +/- GA
AD4 57 F 6 C + - GG
AD6 59 F 5 C +/++ +/++ GA
AD8 63 F 5 C +/- - GG
AD10 70 F 5 C + - GA
AD13 42 M 6 C +/- +/- AA
AD15 54 M 6 C + +/- AA
AD20 58 M 4 C ++ ++ GG
AD42 76 M 5 C + +/- GA
  1. In age-, gender- and genotyped matched MS and AD patients, kif21b protein expression was assessed. NA not applicable, ND not determined or documented.
  2. 1scored as: - no positive cells, +/-1-2 positive cells per field, + maximum of ~30% of the cells positive, ++ ~60% of the cells positive, +++ ~80% positive cells and +++ (virtually) all cells positive.
  3. *time to EDSS 9.0.
  4. Neuropathology assessment based on Braak criteria [12].